INFLUVAC SUB-UNIT, SUSPENSION FOR INJECT 15,15,15 Microgram Suspension for Injection

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181) A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X-223A) B/MASSACHUSETTS/2/2012-LIKE STRAIN (B/MASSACHUSETTS/2/2012, BX-51B)

제공처:

Abbott Healthcare Products Ltd

INN (International Name):

A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009, X-181) A/TEXAS/50/2012 (H3N2)-LIKE STRAIN (A/TEXAS/50/2012, X

복용량:

15,15,15 Microgram

약제 형태:

Suspension for Injection

처방전 유형:

Product subject to prescription which may not be renewed (A)

승인 상태:

Authorised

승인 날짜:

0000-00-00

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Influvac Sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated).
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains*:
- A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, X-181) 15 micrograms HA **
- A/Texas/50/2012 (H3N2)-like strain (A/Texas/50/2012, X-223A) 15 micrograms HA **
- B/Massachusetts/2/2012-like strain (B/Massachusetts/2/2012, BX-51B) 15 micrograms HA **
per 0.5 ml dose
* propagated in fertilised hens’ eggs from healthy chicken flocks
** haemagglutinin.
This vaccine complies with the World Health Organisation (WHO) recommendation (northern hemisphere) and EU
recommendation for the 2014/2015 season.
For a full list of excipients see section 6.1.
Influvac may contain traces of eggs (such as ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium
bromide, polysorbate 80, or gentamicin, which are used during the manufacturing process (see section 4.3).
3 PHARMACEUTICAL FORM
Suspension for injection in prefilled syringes; a colourless clear liquid, filled in single-dose syringes (glass, type I).
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prophylaxis of influenza, especially those who run an increased risk of associated complications.
Influvac is indicated in adults and children from 6 months of age.
The use of Influvac should be based on official recommendations.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
Adults: 0.5 ml.
_Paediatric population_
Children from 36 months onwards: 0.5 ml.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 31/07/2014_
_CRN 2148606_
_page number: 1_
C